Ibrexafungerp citrate is under clinical development by GSK and currently in Phase III for Aspergillosis. According to GlobalData, Phase III drugs for Aspergillosis have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Ibrexafungerp citrate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ibrexafungerp citrate overview

Ibrexafungerp citrate (Brexafemme) is a semi-synthetic triterpenoid derivative of the natural product enfumafungin with potential anti-fungal activity. It is formulated as film coated tablets for oral route of administration. Brexafemme is indicated for the treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (VVC).

Ibrexafungerp citrate (SCY-078) is under development for the treatment of invasive pulmonary aspergillosis, fungal infections, candidiasis (including systemic and invasive), invasive aspergillosis, pneumocystis infections, recurrent vulvovaginal candidiasis, coccidioidomycosis, histoplasmosis, blastomycosis and aspergillosis. It is administered through oral and intravenous route. The drug candidate is a semi-synthetic triterpenoid derivative of the natural product enfumafungin-a structurally distinct class of glucan synthase inhibitors. It acts by targeting beta 1,3-D-glucan synthase.

GSK overview

GSK is a healthcare company that focuses on developing, manufacturing and commercializing general medicines, specialty medicines and vaccines. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular, and urogenital, anti-bacterial, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastrointestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.

For a complete picture of Ibrexafungerp citrate’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.